Beta-blockers in 1st trimester do not up congenital malformations

β-blockers in 1st trimester do not up congenital malformations

(HealthDay)—Maternal use of β-blockers in the first trimester of pregnancy is not associated with a large increase in the risk for overall or cardiac congenital malformations, according to a study published online Oct. 16 in the Annals of Internal Medicine.

Brian T. Bateman, M.D., from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues estimated the risks for major associated with first-trimester exposure to β-blockers using data from health registries in the five Nordic countries and the U.S. Medicaid database.

The researchers found that the β-blocker-associated pooled adjusted relative risk (RR) and difference per 1,000 persons exposed (RD1000) were 1.07 (95 percent confidence interval, 0.89 to 1.3) and 3 (confidence interval, −6.6 to 12.6) for any major malformation; 1.12 (95 percent confidence interval, 0.83 to 1.51) and 2.1 (confidence interval, −4.3 to 8.4) for any cardiac malformation; and 1.97 (95 percent confidence interval, 0.74 to 5.25) and 1 (confidence interval, −0.9 to 3) for cleft lip or palate. Based on the U.S. cohort data only, the adjusted RR and RD1000 were 1.37 (95 percent confidence interval, 0.58 to 3.25) and 1 (confidence interval, −2 to 4) for central nervous system .

"The potential risks to the fetus must be balanced against the risks to the mother associated with untreated hypertension," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further

Risk of venous thromboembolism recurrence high

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Journal information: Annals of Internal Medicine

Copyright © 2018 HealthDay. All rights reserved.

Citation: Beta-blockers in 1st trimester do not up congenital malformations (2018, October 16) retrieved 10 December 2019 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments